Literature DB >> 35829999

Epigallocatechin-3-Gallate Pretreatment Improves Autologous Adipose-derived Stem Cells Against Rheumatoid Arthritis-induced Neuroinflammation in the Brain of Collagen-induced Rats.

Chih-Yang Huang1,2,3,4,5, Da-Tong Ju6, Ming-Shan Chen7,8, Bruce Chi-Kang Tsai9, Maria Angelina Sitorus9, Chia-Hua Kuo10, Wei-Wen Kuo11,12, Tung-Sheng Chen13, Chien-Yao Fu14,15, Tsung-Jung Ho16,17,18.   

Abstract

Adipose tissue-derived mesenchymal stem cells (ADSC) exert neuroprotective and anti-inflammatory effects. ADSCs are considered potential therapeutics for rheumatoid arthritis (RA), an inflammatory, multisystemic autoimmune disease. Epigallocatechin-3-gallate (EGCG), the major polyphenolic compound in green tea, has strong anti-inflammatory and antioxidant properties. This study aimed to investigate whether EGCG has a synergistic effect on the neuroprotective effects of ADSCs to protect the RA-damaged brain. Wistar rats were classified into four groups: sham, RA, RA + ADSCs (1 × 106 cells per rat), and RA + EGCG (10 µM)-pretreated ADSCs. After 2 months of treatment, the brain tissues from the rats were collected and investigated. The brains of RA rats had higher inflammation and apoptosis. ADSC treatment ameliorated these negative effects significantly; however, the neuroprotective abilities of EGCG-pretreated ADSCs were significantly higher than ADSCs. Furthermore, the RA-induced repression of the PI3K/Akt survival pathway was reactivated by EGCG-pretreated ADSCs. Collectively, this study provides evidence that EGCG synergistically enhances the neuroprotective ability of ADSCs to repress the negative effects of RA on the brain. These findings could help develop new therapeutic strategies against RA or other neurodegenerative diseases after clinical validation in the future.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Brain; Epigallocatechin-3-gallate; Neuroprotection; Rheumatoid arthritis; Stem cell

Mesh:

Substances:

Year:  2022        PMID: 35829999     DOI: 10.1007/s12640-022-00544-0

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.978


  4 in total

Review 1.  Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.

Authors:  Josef S Smolen; Daniel Aletaha
Journal:  Nat Rev Rheumatol       Date:  2015-02-17       Impact factor: 20.543

Review 2.  Adipose tissue-derived mesenchymal stem cells as a strategy to improve recovery after stroke.

Authors:  María Gutiérrez-Fernández; Laura Otero-Ortega; Jaime Ramos-Cejudo; Berta Rodríguez-Frutos; Blanca Fuentes; Exuperio Díez-Tejedor
Journal:  Expert Opin Biol Ther       Date:  2015-05-10       Impact factor: 4.388

3.  Prevalence of rheumatoid arthritis in low- and middle-income countries: A systematic review and analysis.

Authors:  Igor Rudan; Simrita Sidhu; Angeliki Papana; Shi-Jiao Meng; Yu Xin-Wei; Wei Wang; Ruth M Campbell-Page; Alessandro Rhyll Demaio; Harish Nair; Devi Sridhar; Evropi Theodoratou; Ben Dowman; Davies Adeloye; Azeem Majeed; Josip Car; Harry Campbell; Wei Wang; Kit Yee Chan
Journal:  J Glob Health       Date:  2015-06       Impact factor: 4.413

4.  Epigallocatechin-3-gallate preconditioned Adipose-derived Stem Cells confer Neuroprotection in aging rat brain.

Authors:  Dennis Jine-Yuan Hsieh; Lawrence Marte; Wei-Wen Kuo; Da-Tong Ju; William Shao-Tsu Chen; Chia-Hua Kuo; Cecilia Hsuan Day; B Mahalakshmi; Po-Hsiang Liao; Chih-Yang Huang
Journal:  Int J Med Sci       Date:  2020-07-19       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.